Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7337382 | 1.00 | TSHR (0.33) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL13508644 | 0.86 | USP2 (0.35) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL8348826 | 0.83 | ALDH1A1 (0.31) | TSHRALDH1A1CYP3A4 | |
| SCHEMBL8348746 | 0.83 | ALDH1A1 (0.31) | TSHRALDH1A1CYP3A4 | |
| SCHEMBL8342800 | 0.81 | ALDH1A1 (0.53) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL4691009 | 0.80 | TSHR (0.43) | TSHRUSP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL8344947 | 0.80 | ALDH1A1 (0.31) | ALDH1A1CYP3A4 | |
| SCHEMBL7617831 | 0.79 | CYP1A2 (0.41) | CYP1A2 | |
| SCHEMBL5909628 | 0.79 | CYP1A2 (0.41) | CYP1A2 | |
| SCHEMBL5909625 | 0.79 | CYP1A2 (0.41) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103334-A1 | Process For Synthesis Of Gabapentin | IPCA LABORATORIES LTD (IN) | 2008-05-01 | — | — | US | disclosed |
| US-4087544-A | Treatment of cranial dysfunctions using novel cyclic amino acids | WARNER-LAMBERT COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
| US-4024175-A | Cyclic amino acids | WARNER-LAMBERT COMPANY (US) | 1977-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103334-A1 | Process For Synthesis Of Gabapentin | GABRB1, GABRD, GABRB2 | TSHR 4585/4885USP2 2856/4885ALDH1A1 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.